Cantor Fitzgerald reissued their buy rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a research report sent to investors on Tuesday morning.

Several other equities research analysts have also recently commented on the stock. Stifel Nicolaus reaffirmed a buy rating and issued a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday. Wells Fargo & Company reaffirmed a buy rating on shares of Jazz Pharmaceuticals PLC in a research report on Tuesday. HC Wainwright began coverage on shares of Jazz Pharmaceuticals PLC in a research report on Friday, August 25th. They issued a neutral rating and a $144.00 price objective on the stock. Cowen and Company set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research report on Monday, August 21st. Finally, Piper Jaffray Companies reaffirmed a buy rating and issued a $177.00 price objective on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $180.96.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 147.57 on Tuesday. The stock has a 50 day moving average price of $151.04 and a 200-day moving average price of $149.06. The stock has a market cap of $8.86 billion, a price-to-earnings ratio of 22.73 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.67 earnings per share. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/jazz-pharmaceuticals-plcs-jazz-buy-rating-reiterated-at-cantor-fitzgerald/1537197.html.

In other news, Director Paul L. Berns sold 662 shares of the business’s stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $142.37, for a total transaction of $94,248.94. Following the transaction, the director now directly owns 6,599 shares in the company, valued at approximately $939,499.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the business’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $150.65, for a total transaction of $30,130.00. Following the transaction, the executive vice president now owns 22,223 shares in the company, valued at $3,347,894.95. The disclosure for this sale can be found here. Insiders have sold a total of 7,917 shares of company stock worth $1,223,227 over the last three months. Insiders own 4.30% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Somerset Trust Co raised its position in Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock valued at $497,000 after buying an additional 14 shares in the last quarter. Level Four Advisory Services LLC raised its position in Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock valued at $389,000 after buying an additional 23 shares in the last quarter. World Asset Management Inc raised its position in Jazz Pharmaceuticals PLC by 1.9% in the second quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 27 shares in the last quarter. Profund Advisors LLC raised its position in Jazz Pharmaceuticals PLC by 1.3% in the second quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock valued at $453,000 after buying an additional 38 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its position in Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock valued at $217,000 after buying an additional 44 shares in the last quarter. Institutional investors own 88.24% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.